Interleukin-2 therapy in HIV infection

Savita G Pahwa, Maripaz Morales

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Immune cells secrete a variety of cytokines that have a profoundly significant influence on the immune system. For example, cytokines secreted by T-helper cells have a role in cellular immune response (Th1 cytokines) and in antibody production (Th2 cytokines). Interleukin 2 (IL-2) is used therapeutically for immune modulation, most specifically in cancer therapy. The following report describes the mechanisms of IL-2/IL-2 receptor interaction and summarizes the rationale for using IL-2 in HIV-infected patients and briefly describes recent and ongoing clinical trials using IL-2 in HIV/AIDS disease (intravenous IL-2 therapy and subcutaneous IL-2 therapy). In one study of patients with moderate stage HIV disease, subjects taking a maximum tolerated dose of IL-2 at 12 to 15 MIU/day demonstrated durable increases in CD4 counts and a near normal return in value. Relative to the published reports, low circulating CD4 counts and high HIV viral burden appeared to be independent determinants of a poor response to IL-2. However, aggressive combination therapy with IL-2 and highly active antiretroviral therapy (HAART) (e.g., ACTG 328) holds promise for an improved immune restorative response even in patients with advanced disease.

Original languageEnglish
Pages (from-to)187-197
Number of pages11
JournalAIDS Patient Care and STDs
Volume12
Issue number3
StatePublished - Apr 15 1998
Externally publishedYes

Fingerprint

HIV Infections
Interleukin-2
HIV
Cytokines
Therapeutics
CD4 Lymphocyte Count
Maximum Tolerated Dose
Interleukin-2 Receptors
Highly Active Antiretroviral Therapy
Helper-Inducer T-Lymphocytes
Viral Load
Cellular Immunity
Antibody Formation
Immune System
Acquired Immunodeficiency Syndrome
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Leadership and Management
  • Nursing(all)

Cite this

Interleukin-2 therapy in HIV infection. / Pahwa, Savita G; Morales, Maripaz.

In: AIDS Patient Care and STDs, Vol. 12, No. 3, 15.04.1998, p. 187-197.

Research output: Contribution to journalArticle

Pahwa, SG & Morales, M 1998, 'Interleukin-2 therapy in HIV infection', AIDS Patient Care and STDs, vol. 12, no. 3, pp. 187-197.
Pahwa, Savita G ; Morales, Maripaz. / Interleukin-2 therapy in HIV infection. In: AIDS Patient Care and STDs. 1998 ; Vol. 12, No. 3. pp. 187-197.
@article{a885fba145bc4d9e8cd6a1a856cfd349,
title = "Interleukin-2 therapy in HIV infection",
abstract = "Immune cells secrete a variety of cytokines that have a profoundly significant influence on the immune system. For example, cytokines secreted by T-helper cells have a role in cellular immune response (Th1 cytokines) and in antibody production (Th2 cytokines). Interleukin 2 (IL-2) is used therapeutically for immune modulation, most specifically in cancer therapy. The following report describes the mechanisms of IL-2/IL-2 receptor interaction and summarizes the rationale for using IL-2 in HIV-infected patients and briefly describes recent and ongoing clinical trials using IL-2 in HIV/AIDS disease (intravenous IL-2 therapy and subcutaneous IL-2 therapy). In one study of patients with moderate stage HIV disease, subjects taking a maximum tolerated dose of IL-2 at 12 to 15 MIU/day demonstrated durable increases in CD4 counts and a near normal return in value. Relative to the published reports, low circulating CD4 counts and high HIV viral burden appeared to be independent determinants of a poor response to IL-2. However, aggressive combination therapy with IL-2 and highly active antiretroviral therapy (HAART) (e.g., ACTG 328) holds promise for an improved immune restorative response even in patients with advanced disease.",
author = "Pahwa, {Savita G} and Maripaz Morales",
year = "1998",
month = "4",
day = "15",
language = "English",
volume = "12",
pages = "187--197",
journal = "AIDS Patient Care and STDs",
issn = "1087-2914",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Interleukin-2 therapy in HIV infection

AU - Pahwa, Savita G

AU - Morales, Maripaz

PY - 1998/4/15

Y1 - 1998/4/15

N2 - Immune cells secrete a variety of cytokines that have a profoundly significant influence on the immune system. For example, cytokines secreted by T-helper cells have a role in cellular immune response (Th1 cytokines) and in antibody production (Th2 cytokines). Interleukin 2 (IL-2) is used therapeutically for immune modulation, most specifically in cancer therapy. The following report describes the mechanisms of IL-2/IL-2 receptor interaction and summarizes the rationale for using IL-2 in HIV-infected patients and briefly describes recent and ongoing clinical trials using IL-2 in HIV/AIDS disease (intravenous IL-2 therapy and subcutaneous IL-2 therapy). In one study of patients with moderate stage HIV disease, subjects taking a maximum tolerated dose of IL-2 at 12 to 15 MIU/day demonstrated durable increases in CD4 counts and a near normal return in value. Relative to the published reports, low circulating CD4 counts and high HIV viral burden appeared to be independent determinants of a poor response to IL-2. However, aggressive combination therapy with IL-2 and highly active antiretroviral therapy (HAART) (e.g., ACTG 328) holds promise for an improved immune restorative response even in patients with advanced disease.

AB - Immune cells secrete a variety of cytokines that have a profoundly significant influence on the immune system. For example, cytokines secreted by T-helper cells have a role in cellular immune response (Th1 cytokines) and in antibody production (Th2 cytokines). Interleukin 2 (IL-2) is used therapeutically for immune modulation, most specifically in cancer therapy. The following report describes the mechanisms of IL-2/IL-2 receptor interaction and summarizes the rationale for using IL-2 in HIV-infected patients and briefly describes recent and ongoing clinical trials using IL-2 in HIV/AIDS disease (intravenous IL-2 therapy and subcutaneous IL-2 therapy). In one study of patients with moderate stage HIV disease, subjects taking a maximum tolerated dose of IL-2 at 12 to 15 MIU/day demonstrated durable increases in CD4 counts and a near normal return in value. Relative to the published reports, low circulating CD4 counts and high HIV viral burden appeared to be independent determinants of a poor response to IL-2. However, aggressive combination therapy with IL-2 and highly active antiretroviral therapy (HAART) (e.g., ACTG 328) holds promise for an improved immune restorative response even in patients with advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=0031920282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031920282&partnerID=8YFLogxK

M3 - Article

C2 - 11361933

AN - SCOPUS:0031920282

VL - 12

SP - 187

EP - 197

JO - AIDS Patient Care and STDs

JF - AIDS Patient Care and STDs

SN - 1087-2914

IS - 3

ER -